Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XMT-1107 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| XMT-1107 | EXPERIMENTAL | Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m\^2, doubling in dose to 24 mg/m\^2, then 40 mg/m\^2, then 60 mg/m\^2, then 80 mg/m\^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced. |
| Name | Type | Description |
|---|---|---|
| XMT-1107 | DRUG | 6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops |
Inclusion Criteria: * Patient must have a histological diagnosis of advanced solid tumor and must be refractory to standard therapy or have no effective therapy. * Measurable or evaluable disease. * At least 42 days since administration of mitomycin or nitrosoureas and 28 days since any other chemo...
XMT-1107 is an investigational small molecule being studied for the treatment of neoplasm metastasis, which refers to cancer that has spread from its original site to other parts of the body. It is being developed as a potential oncology therapy for patients with advanced solid tumors.
XMT-1107 is being developed by Day One Biopharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol DAWN. The company is focused on advancing this investigational oncology drug candidate through clinical development.
XMT-1107 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with advanced solid tumors.
XMT-1107 has one completed clinical trial, identified as NCT01011972, titled "A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors." This Phase 1 study enrolled 52 participants in the United States and included adults aged 18 years and older.
XMT-1107 is administered intravenously, as indicated by the clinical trial NCT01011972, which evaluated intravenous XMT-1107 in patients with advanced solid tumors. The study was uncontrolled, meaning there was no comparison group, and it was not randomized or double-blinded.